Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism

Bradley N. Spatolaa Antibody Development, Tizona Therapeutics, South San Francisco, CA, USACorrespondence[email protected]

Alana G. Lernerb Immunology, Tizona Therapeutics, South San Francisco, CA, USA

Clifford Wonga Antibody Development, Tizona Therapeutics, South San Francisco, CA, USA

Tracy dela Cruzb Immunology, Tizona Therapeutics, South San Francisco, CA, USA;c Immunology, Trishula Therapeutics, South San Francisco, CA, USA

Megan Welchb Immunology, Tizona Therapeutics, South San Francisco, CA, USA

Wanchi Funga Antibody Development, Tizona Therapeutics, South San Francisco, CA, USA

Maria Kovalenkod Clinical Biomarkers, AbbVie, Redwood City, CA, USA

Karolina Losenkovae MediCity Research Laboratory, University of Turku, Turku, Finland

Gennady G. Yegutkine MediCity Research Laboratory, University of Turku, Turku, Finland

Courtney Beersb Immunology, Tizona Therapeutics, South San Francisco, CA, USA

John Corbina Antibody Development, Tizona Therapeutics, South San Francisco, CA, USA

Vanessa B. Sorosa Antibody Development, Tizona Therapeutics, South San Francisco, CA, USA

Your download is now in progress and you may close this window